Loading institutional data...
Loading institutional data...
Institutional distribution: ownership decreased -0.70% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Top 22 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M 100.0% | $54.4M 100.0% | $53.4M 100.0% | $50.3M 100.0% | $56.2M 100.0% | $55.4M 100.0% | $39.7M 100.0% | $37.1M 100.0% | $30.0M 100.0% | $6.8M 100.0% |
| Cost of Revenue | $57.4M 87.9% | $50.1M 92.1% | $49.0M 91.9% | $44.4M 88.2% | $47.9M 85.2% | $47.3M 85.5% | $36.0M 90.8% | $34.7M 93.5% | $28.1M 93.5% | $6.2M 91.1% |
| Gross Profit | $7.9M 12.1% | $4.3M 7.9% | $4.3M 8.1% | $6.0M 11.8% | $8.3M 14.8% | $8.1M 14.5% | $3.7M 9.2% | $2.4M 6.5% | $2.0M 6.5% | $601K 8.9% |
| Research & Development | $519K 0.8% | $533K 1.0% | $165K 0.3% | — | — | — | — | — | — | — |
| Selling, General & Admin | $15.6M 23.9% | $11.7M 21.6% | $19.6M 36.8% | $10.2M 20.2% | $9.2M 16.4% | $2.1M 3.8% | $3.3M 8.3% | $3.6M 9.7% | $4.9M 16.2% | $794K 11.8% |
| Total Operating Expenses | $24.6M 37.7% | $19.9M 36.5% | $26.2M 49.0% | $13.4M 26.7% | $12.9M 22.9% | $5.3M 9.6% | $3.9M 9.9% | $3.6M 9.8% | $6.8M 22.8% | $804K 11.9% |
| Operating Income | -$16.7M -25.6% | -$15.5M -28.6% | -$21.8M -40.9% | -$7.5M -14.8% | -$4.5M -8.1% | $2.7M 4.9% | -$256K -0.6% | -$1.2M -3.3% | -$4.9M -16.2% | -$203K -3.0% |
| Interest Expense | $1.9M 2.9% | $1.0M 1.9% | $866K 1.6% | $2.3M 4.7% | $2.8M 5.0% | $2.8M 5.0% | -$1.4M -3.6% | -$968K -2.6% | $748K 2.5% | $190K 2.8% |
| Interest & Investment Income | $396K 0.6% | $406K 0.7% | $663K 1.2% | $236K 0.5% | $46K 0.1% | $66K 0.1% | $0 0.0% | — | — | — |
| Other Income (Expense), net | -$2.4M -3.7% | -$638K -1.2% | $3.3M 6.2% | -$5.6M -11.1% | -$3.3M -5.9% | -$1.5M -2.7% | -$2.9M -7.2% | -$7.8M -21.1% | — | — |
| Pretax Income | -$19.1M -29.3% | -$16.2M -29.7% | -$18.5M -34.7% | -$13.1M -25.9% | -$7.8M -14.0% | $1.2M 2.2% | -$3.1M -7.9% | -$9.0M -24.4% | -$6.2M -20.7% | -$600K -8.9% |
| Income Tax Expense | $0 0.0% | $0 0.0% | $0 0.0% | -$775K -1.5% | $114K 0.2% | -$378K -0.7% | $183K 0.5% | -$17K -0.0% | $3K 0.0% | $769 0.0% |
| Net Income | -$19.1M -29.3% | -$16.2M -29.7% | -$18.5M -34.7% | -$13.8M -27.5% | -$8.0M -14.2% | $821K 1.5% | -$3.3M -8.3% | -$9.1M -24.4% | -$6.2M -20.7% | -$601K -8.9% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.63 | $-1.17 | $-2.15 | $-33.16 | $-23.74 | $0.06 | $-0.25 | $-0.68 | $-0.49 | $0.00 |
| EPS (Diluted) | $-0.63 | $-1.17 | $-2.15 | $-33.16 | $-23.74 | $0.06 | $-0.25 | $-0.68 | $-0.49 | $80741.00 |
| Weighted Avg Shares (Basic) | 30.3M | 19.1M | 12.0M | 1.9M | 657K | 13.3M | 13.3M | 13.3M | 12.8M | 12.6M |
| Weighted Avg Shares (Diluted) | 30.3M | 19.1M | — | 1.9M | 657K | 13.3M | 13.3M | 13.3M | 12.8M | 125.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$9M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -86%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $715674 is below the $2M due within a year — relies on refinancing or operating cash flow. Scheduled principal only (excludes interest & revolver draws). As of 2026-03-31 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~50.3% on $4M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 4th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 93.5 | 90.8 | 85.5 | 85.2 | 88.2 | 91.9 | 92.1 | 87.9 |
| Gross Profit | 6.5 | 9.2 | 14.5 | 14.8 | 11.8 | 8.1 | 7.9 | 12.1 |
| R&D | — | — | — | — | — | 0.3 | 1.0 | 0.8 |
| SG&A | 9.7 | 8.3 | 3.8 | 16.4 | 20.2 | 36.8 | 21.6 | 23.9 |
| Operating Income | -3.3 | -0.6 | 4.9 | -8.1 | -14.8 | -40.9 | -28.6 | -25.6 |
| Income Tax | -0.0 | 0.5 | -0.7 | 0.2 | -1.5 | 0.0 | 0.0 | 0.0 |
| Net Income | -24.4 | -8.3 | 1.5 | -14.2 | -27.5 | -34.7 | -29.7 | -29.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on COSM: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| COSM | $6M | — | — | 0.1× | 19.9% | 12.1% | -29.3% | -104% | -86.2% | -0.2× | 22 |
Peers = companies sharing COSM's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.